3
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Papillomavirus Infections
9
Uterine Cervical Neoplasms
4
Neuroendocrine Tumors
4
Autoimmune Diseases
3
Prostatic Neoplasms
2
Neoplasms
2
Abortion, Spontaneous
2
Recurrence
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Neuroblastoma
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Myasthenia Gravis
1
Lymphohistiocytosis, Hemophagocytic
1
Lung Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
tusamitamab ravtansine
2
Ramucirumab
2
Docetaxel
2
telomerase reverse transcriptase p572Y, human
1
pembrolizumab
1
necitumumab
1
Paclitaxel
1
LY3023414
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Data Collection
1
Carboplatin
1
Bevacizumab
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Non-small Cell Lung Cancer Metastatic
×
Data Collection
×
Clear all
NCT04994795
2024-11-21
DEEP-Lung-IV
Sophia Genetics SAS
Active not recruiting
4,000 enrolled